Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Indiplon-IR: NBIX completed enrollment of 500 patients in an interantional Phase III trial of indiplon-IR. The company plans to conduct a total of eight Phase I

Neurocrine Biosciences Inc. (NBIX), San Diego, Calif.
Product: Indiplon-IR

Read the full 90 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE